FindTrial
Sign In

Effect of N-acetyl Cysteine (NAC) on contrast-induced nephropathy in patients with basal urinary neutrophil gelatinase-associated lipocalin (NGAL) positive underwent angiography or coronary intervention (PCI): A single blind randomized clinical trial

Effect of N-acetyl Cysteine (NAC) on contrast-induced nephropathy in patients with basal urinary neutrophil gelatinase-associated lipocalin (NGAL) positive underwent angiography or coronary intervention (PCI): A single blind randomized clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190311043011N1
Enrollment
110
Registered
2019-03-17
Start date
2019-03-11
Completion date
Unknown
Last updated
2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contrast- Induced Nephropathy disease. Other acute kidney failure

Interventions

Intervention 1: Oral acetylcysteine (NAC) tablet of 1200 mg twice daily for 3 days. Intervention 2: Control group: Venous hydration 2-3cc / kg.

Sponsors

Hamedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Age 18 to 90 years Undergoing angiography or coronary artery intervention

Exclusion criteria

Exclusion criteria: Kidney disease Urinary tract infection Urinary tract tumor Use of Nephrotoxic or Antibiotic drugs or contrast media within past week

Design outcomes

Primary

MeasureTime frame
Serum creatinine. Timepoint: Before and 48 hours after the intervention. Method of measurement: blood test.;Neutrophil Gelatinase Associated Lipocalin. Timepoint: Before the intervention. Method of measurement: Urine Test.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzadeh Mozayani Monfared

Hamedan University of Medical Sciences

azadeh_m27@yahoo.com+98 81 3838 1720

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026